LOINC
Version 2.73

LP171382-7AbciximabActive

Description

LP171382-7   Abciximab
Abciximab is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.

Many of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal hemorrhage.

Thrombocytopenia is a rare but known serious risk. Abciximab-induced thrombocytopenia can typically be treated with transfusion of platelets. Abciximab induced thrombocytopenia can last for seven days after initial drug administration. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, Abciximab

Basic Part Properties

Name
Abciximab
Type
Component
Created On
2012-12-19
Construct for LOINC Short Name
Abciximab

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP171382-7

Language Variants Get Info

zh-CNChinese (China)
阿昔单抗
Synonyms: 阿西单抗;阿昔;阿西;Abciximab;platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor;血小板表面糖蛋白受体 (GPⅡb/Ⅲa)拮抗剂;血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂;血小板糖蛋白Iib/IIIa受体拮抗剂;血小板糖蛋白Ⅱb/Ⅲa受体抑制剂;ReoPro;阿昔单克隆抗体
nl-NLDutch (Netherlands)
abciximab
it-ITItalian (Italy)
Abciximab
ru-RURussian (Russian Federation)
Абциксимаб
es-ESSpanish (Spain)
Abciximab
tr-TRTurkish (Turkey)
Abciximab